Open Actively Recruiting

Study of Onvansertib in Combination with FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants with a KRAS or NRAS Mutation

About

Brief Summary

The purpose of this study is to assess 2 different doses of onvansertib to select the lowest dose that is maximally effective, and to assess the safety, efficacy, pharmacokinetics, and pharmacodynamics of onvansertib in combination with FOLFIRI + bevacizumab or FOLFOX + bevacizumab in patients with KRAS or NRAS-mutated metastatic colorectal cancer (CRC) in the first-line setting.

Primary Purpose
Treatment
Study Type
Interventional
Phase
Phase 2

Eligibility

Gender
All
Healthy Volunteers
No
Minimum Age
18 Years
Maximum Age
N/A

Inclusion Criteria:

Exclusion Criteria:

Join this Trial

Share:
Study Stats
Protocol No.
24-000127
Category
Colorectal Cancer
Contact
Ruth Gonzalez
Location
  • TRIO-US - Bakersfield
  • TRIO-US - Ft. Wayne IN
  • TRIO-US - Jonesboro AR
  • TRIO-US - Redondo Beach
  • TRIO-US - Whittier
  • TRIO-US - Wichita KS
  • UCLA Burbank
  • UCLA Encino
  • UCLA Irvine
  • UCLA Laguna Hills
  • UCLA Pasadena
  • UCLA Porter Ranch
  • UCLA San Luis Obispo
  • UCLA Santa Barbara
  • UCLA Santa Clarita
  • UCLA Santa Monica
  • UCLA Torrance
  • UCLA Ventura
  • UCLA Westlake Village
  • UCLA Westwood
For Providers
NCT No.
NCT06106308
For detailed technical eligibility, visit ClinicalTrials.gov.